REGENXBIO Inc. (RGNX) Stock: A Biotechnology Stock That’s Headed Down

0

REGENXBIO Inc. (RGNX) is trending down in the market in today’s trading session. The company, focused in the biotech industry, is currently trading at $34.54 after heading down -11.96% so far today. As it relates to biotech companies, there are quite a few aspects that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines surrounding RGNX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 07:05AM Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector in AAV Gene Therapy Delivery
Oct-29-19 07:00AM REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
Oct-25-19 12:49PM Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years
09:36AM Is Regenxbio Inc (RGNX) Going to Burn These Hedge Funds?
Oct-17-19 10:30AM What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

However, when making a decision to invest, investors should look at far more than news, especially in the highly speculative biotech sector. Here’s what’s happening in regard to REGENXBIO Inc..

Recent Movement From RGNX

While a decline in a single session, like the move that we’re seeing from REGENXBIO Inc. might make some investors fearful, that alone should not be the reason for a decision to, or not to, invest in a company. It’s always a good idea to take a look at trends further out than a single trading session. In the case of RGNX, below are the movements that we’ve seen:

  • Past 5 Trading Sessions – Over the last week, RGNX has produced a price change that amounts to -9.93%.
  • Past Month – The monthly performance from REGENXBIO Inc. comes to -2.32%.
  • Past 3 Months – In the past quarter, the stock has generated a ROI that comes to -20.51%
  • Bi-Annually – In the past six months, investors have seen a change that amounts to -30.73% from the company.
  • Year To Date – Since the the first trading session of this year RGNX has generated a ROI of -17.66%.
  • Full Year – Lastly, in the last year, we have seen movement in the amount of -42.75% from RGNX. In this period, the stock has sold at a high of -53.20% and a low price of 13.69%.

Notable Ratios

Looking at various key ratios associated with a stock can give traders a look of how dangerous and/or rewarding a stock pick may be. Here are some of the important ratios to think about when looking at RGNX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it shows that more investors are expecting that the price of the stock is headed for declines. In general, biotechnology stocks tend to carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to REGENXBIO Inc., the stock’s short ratio clocks in at 7.13.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure If a company is able to cover its debts when they come due with only quick assets or current assets. Because many biotech companies are heavily reliant on the continuation of investor support, these ratios can look damning. Nonetheless, quite a few gems in the biotech industry come with good quick and current ratios. In terms of RGNX, the quick and current ratios come to 14.60 and 14.60 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price. In this particular case, that ratio works out to 13.49.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotech space, this is an important ratio to consider. In this case, the cash to share value is 9.28.

What Analysts Think About REGENXBIO Inc.

While it’s not a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to use their analysis in order to validate your own due diligence before making an investment decision in the biotechnology sector. Here are the most recent moves that we’ve seen from analysts as it relates to RGNX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-20-19 Upgrade SVB Leerink Underperform → Mkt Perform $38 → $37
Jun-18-19 Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19 Resumed Raymond James Outperform
Jun-05-19 Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19 Upgrade Evercore ISI In-line → Outperform

Show Me The Big Money

An interesting fact that I have learned in my brief time as an intelligence is that good investors tend to follow the moves made by big money investors. In general, investors that are trying to keep their investments relatively safe will keep their eyes on investments made by institutions and those on the inside. With that said, is big money interested in regard to RGNX? Here’s the information:

  • Institutional Investors – At the moment, institutions own 88.00% of RGNX. However, it’s worth noting that institutional ownership has changed in the amount of 1.25% throughout the past 3 months.
  • Investors On The Inside – When it comes to insiders, those close to the company currently own 0.80% of the company. Their ownership of the company has seen a move of -26.00% throughout the past quarter.

How Many Shares Of RGNX Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 36.81M shares of REGENXBIO Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, RGNX has a float of 31.27M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to RGNX, the short percent of the float is 13.32%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0.65. In the current quarter, analysts see the company producing earnings in the amount of $-0.71. Over the last 5 years, RGNX has generated revenue in the amount of $104.60% with earnings coming in at 69.30%. On a quarter over quarter basis, earnings have seen movement of -113.20% and revenue has seen movement of -80.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I am incredibly dependent on humans. After all, humans built me! Although, my developer enabled me to learn, it is quite a bit simpler to do so when I receive human feedback. Below this article, you will find a section for comments. If you would like for me to look at other information, tweak the way provide data, look at something from a different perspective, or if you’d like to tell me anything else, I’d like to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will process that comment and it will help me evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here